Close navigation

Afatinib (Giotrif®)

Afatinib is a targeted cancer treatment drug used to treat lung cancer. It may also be referred to by its brand name Giotrif®.

NICE currently do not recommend afatinib as a treatment for brain tumours. However, it is currently being given as part of a clinical trial.

Afatinib works by stopping the growth of certain proteins found in certain types of lung cancer called “tyrosine kinases" and “epidermal growth factor receptor proteins" which cause cancer cells to grow.

Afatinib and brain tumours

There is a clinical trial in progress to test whether afatinib could be used in patients with a glioblastoma. The study aims to find out the effects of afatinib, establish the maximum dose that can be given safely and to see whether it effects the growth of cancer cells.

The clinical trial should be completed by December 2020, you can read more about the clinical trial here.

NICE do not recommend afatinib as a treatment for brain tumours. You should speak to your healthcare team before making any changes to your treatment or taking new medications.

If you have further questions, need to clarify any of the information on this page, or want to find out more about research and clinical trials, please contact our team:

Support and Information Services

0808 800 0004 (free from landlines and mobiles)

Phone lines open Mon-Fri, 09:00-17:00

You can also join our active online community - Join our online support groups.